Aquestive (AQST) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$54.1M

Revenue (quarter)

$13.8M

Revenue growth (year over year)

+38.15%

Gross profit (trailing twelve months)

$54.1M

Gross margin

100.00%

Net income (trailing twelve months)

−$78.2M

Net income (quarter)

−$22.9M

Net income growth (year over year)

−68.76%

Net margin

−144.63%

Return on equity

—

EPS (trailing twelve months)

−$0.66

Book value per share

−$0.45

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

142.83%

Payout ratio

—

Dividend yield

—

Company profile

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

• Is Aquestive (AQST) profitable?

  No. Aquestive reported a net loss of $78.2M over the trailing twelve months.

• How much revenue does Aquestive (AQST) make?

  Aquestive generated $54.1M in revenue over the trailing twelve months, up 38.15% year over year.

• How do I buy stock in Aquestive (AQST)?

  AQST trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.